Carisma Therapeutics, Inc.
US ˙ NasdaqCM ˙ US14216R1014

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Flagship Ventures Fund IV General Partner LLC. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Flagship Ventures Fund IV General Partner LLC har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:EVLO / Evelo Biosciences, Inc. 10% Owner 3.931.685
US:AXLA / Axcella Health Inc. 10% Owner 3.048.780
US:RUBY / Rubius Therapeutics, Inc. 10% Owner 2.633.703
US:KLDO / Kaleido Biosciences, Inc. 10% Owner 738.333
US:MCRB / Seres Therapeutics, Inc. 10% Owner 0
US:MRNA / Moderna, Inc. Director, 10% Owner 0
US:TMDX / TransMedics Group, Inc. 10% Owner 0
US:SYRS / Syros Pharmaceuticals, Inc. 10% Owner 0
US:EBIO / Eleven Biotherapeutics, Inc. 10% Owner 106.787
US:EDIT / Editas Medicine, Inc. 10% Owner 0
US:TTOO / T2 Biosystems, Inc. 10% Owner 0
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Flagship Ventures Fund IV General Partner LLC. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb CARM / Carisma Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2014-02-11 EBIO Flagship Ventures Fund 2007, L.P. 214.095 10,0000 214.095 10,0000 2.140.950 730
2014-02-11 EBIO Flagship Ventures Fund 2007, L.P. 131.722 10,0000 131.722 10,0000 1.317.220
2014-02-11 EBIO Flagship Ventures Fund 2007, L.P. 32.912 10,0000 32.912 10,0000 329.120

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

CARM / Carisma Therapeutics, Inc. Insider Trades
Insidersalg CARM / Carisma Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2016-09-23 EBIO Flagship Ventures Fund IV, L.P. 12.482 3,1600 12.482 3,1600 39.443 730
2016-09-23 EBIO Flagship Ventures Fund IV, L.P. 3.118 3,1600 3.118 3,1600 9.853
2016-09-23 EBIO Flagship Ventures Fund IV, L.P. 41.178 3,1000 41.178 3,1000 127.652
2016-09-23 EBIO Flagship Ventures Fund IV, L.P. 10.293 3,1000 10.293 3,1000 31.908
2016-09-22 EBIO Flagship Ventures Fund IV, L.P. 112.731 3,1800 112.731 3,1800 358.485
2016-09-22 EBIO Flagship Ventures Fund IV, L.P. 28.163 3,1800 28.163 3,1800 89.558
2016-09-22 EBIO Flagship Ventures Fund IV, L.P. 188.367 3,1700 188.367 3,1700 597.123
2016-09-22 EBIO Flagship Ventures Fund IV, L.P. 47.090 3,1700 47.090 3,1700 149.275
2016-09-21 EBIO Flagship Ventures Fund IV, L.P. 258.214 3,7500 258.214 3,7500 968.302
2016-09-21 EBIO Flagship Ventures Fund IV, L.P. 64.509 3,7500 64.509 3,7500 241.909
2016-09-20 EBIO Flagship Ventures Fund IV, L.P. 43.139 3,3900 43.139 3,3900 146.241
2016-09-20 EBIO Flagship Ventures Fund IV, L.P. 10.778 3,3900 10.778 3,3900 36.537
2016-09-19 EBIO Flagship Ventures Fund IV, L.P. 7.761 3,3100 7.761 3,3100 25.689
2016-09-19 EBIO Flagship Ventures Fund IV, L.P. 1.939 3,3100 1.939 3,3100 6.418
2016-09-15 EBIO Flagship Ventures Fund IV, L.P. 2.145 4,1600 2.145 4,1600 8.923
2016-09-15 EBIO Flagship Ventures Fund IV, L.P. 536 4,1600 536 4,1600 2.230
2016-09-14 EBIO Flagship Ventures Fund IV, L.P. 35.209 4,1800 35.209 4,1800 147.174
2016-09-14 EBIO Flagship Ventures Fund IV, L.P. 8.802 4,1800 8.802 4,1800 36.792
2016-09-07 EBIO Flagship Ventures Fund IV, L.P. 52.985 4,5100 52.985 4,5100 238.962
2016-09-07 EBIO Flagship Ventures Fund IV, L.P. 32.597 4,5100 32.597 4,5100 147.012
2016-09-07 EBIO Flagship Ventures Fund IV, L.P. 8.145 4,5100 8.145 4,5100 36.734
2016-09-06 EBIO Flagship Ventures Fund IV, L.P. 20.221 4,6300 20.221 4,6300 93.623
2016-09-06 EBIO Flagship Ventures Fund IV, L.P. 12.441 4,6300 12.441 4,6300 57.602
2016-09-06 EBIO Flagship Ventures Fund IV, L.P. 3.108 4,6300 3.108 4,6300 14.390

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

CARM / Carisma Therapeutics, Inc. Insider Trades
Insiderkøb EDIT / Editas Medicine, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

EDIT / Editas Medicine, Inc. Insider Trades
Insidersalg EDIT / Editas Medicine, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

EDIT / Editas Medicine, Inc. Insider Trades
Insiderkøb EVLO / Evelo Biosciences, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2023-07-11 EVLO Flagship Ventures Fund IV General Partner LLC 1.082.251 2,3100 1.082.251 2,3100 2.500.000 35 13.3100 11.904.762 476,19
2023-07-11 EVLO Flagship Ventures Fund IV General Partner LLC 1.082.251 2,3100 1.082.251 2,3100 2.500.000
2023-07-11 EVLO Flagship Ventures Fund IV General Partner LLC 3.246.753 2,3100 3.246.753 2,3100 7.499.999
2022-05-27 EVLO Flagship Ventures Fund IV General Partner LLC 4.383.561 1,4600 219.178 29,2000 6.399.999
2022-05-27 EVLO Flagship Ventures Fund IV General Partner LLC 1.095.890 1,4600 54.794 29,2000 1.599.999
2022-05-27 EVLO Flagship Ventures Fund IV General Partner LLC 1.369.863 1,4600 68.493 29,2000 2.000.000
2022-05-27 EVLO Flagship Ventures Fund IV General Partner LLC 6.849.315 1,4600 342.466 29,2000 10.000.000
2022-05-27 EVLO Flagship Ventures Fund IV General Partner LLC 13.698.630 1,4600 684.932 29,2000 20.000.000
2021-02-02 EVLO Flagship Ventures Fund IV General Partner LLC 37.143 15,0000 1.857 300,0000 557.145
2021-02-02 EVLO Flagship Ventures Fund IV General Partner LLC 9.285 15,0000 464 300,0000 139.275
2021-02-02 EVLO Flagship Ventures Fund IV General Partner LLC 37.143 15,0000 1.857 300,0000 557.145
2021-02-02 EVLO Flagship Ventures Fund IV General Partner LLC 46.429 15,0000 2.321 300,0000 696.435
2020-06-29 EVLO Flagship Ventures Fund IV General Partner LLC 1.333.333 3,7500 66.667 75,0000 4.999.999
2020-06-29 EVLO Flagship Ventures Fund IV General Partner LLC 333.333 3,7500 16.667 75,0000 1.249.999
2020-06-29 EVLO Flagship Ventures Fund IV General Partner LLC 1.333.333 3,7500 66.667 75,0000 4.999.999
2020-06-29 EVLO Flagship Ventures Fund IV General Partner LLC 1.666.667 3,7500 83.333 75,0000 6.250.001

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

EVLO / Evelo Biosciences, Inc. Insider Trades
Insidersalg EVLO / Evelo Biosciences, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

EVLO / Evelo Biosciences, Inc. Insider Trades
Insiderkøb KLDO / Kaleido Biosciences, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2021-02-08 KLDO Flagship Ventures Fund IV General Partner LLC 71.666 11,5000 71.666 11,5000 824.159 3 12.18 48.733 5,91
2021-02-08 KLDO Flagship Ventures Fund IV General Partner LLC 71.667 11,5000 71.667 11,5000 824.170
2021-02-08 KLDO Flagship Ventures Fund IV General Partner LLC 71.667 11,5000 71.667 11,5000 824.170
2020-06-04 KLDO Flagship Ventures Fund IV General Partner LLC 666.667 7,5000 666.667 7,5000 5.000.002
2020-06-04 KLDO Flagship Ventures Fund IV General Partner LLC 666.667 7,5000 666.667 7,5000 5.000.002
2020-06-04 KLDO Flagship Ventures Fund IV General Partner LLC 666.666 7,5000 666.666 7,5000 4.999.995

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

KLDO / Kaleido Biosciences, Inc. Insider Trades
Insidersalg KLDO / Kaleido Biosciences, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

KLDO / Kaleido Biosciences, Inc. Insider Trades
Insiderkøb MCRB / Seres Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

MCRB / Seres Therapeutics, Inc. Insider Trades
Insidersalg MCRB / Seres Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2016-05-25 MCRB AFEYAN NOUBAR 320.562 27,6000 16.028 552,0000 8.847.511 203 8.9900 -8.703.419 -98,37
2016-05-25 MCRB AFEYAN NOUBAR 80.141 27,6000 4.007 552,0000 2.211.892
2016-05-25 MCRB AFEYAN NOUBAR 599.297 27,6000 29.965 552,0000 16.540.597

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

MCRB / Seres Therapeutics, Inc. Insider Trades
Insiderkøb SYRS / Syros Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2016-07-06 SYRS Flagship Ventures Fund IV, L.P. 320.000 12,5000 32.000 125,0000 4.000.000 348 185.7 1.942.400 48,56
2016-07-06 SYRS Flagship Ventures Fund IV, L.P. 80.000 12,5000 8.000 125,0000 1.000.000

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Insidersalg SYRS / Syros Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Insiderkøb TMDX / TransMedics Group, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TMDX / TransMedics Group, Inc. Insider Trades
Insidersalg TMDX / TransMedics Group, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TMDX / TransMedics Group, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Flagship Ventures Fund IV General Partner LLC som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2023-07-13 2023-07-11 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 3.246.753 3.931.685 474,03 2,31 7.499.999 9.082.192
2023-07-13 2023-07-11 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 1.082.251 1.493.241 263,33 2,31 2.500.000 3.449.387
2023-07-13 2023-07-11 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 1.082.251 1.493.241 263,33 2,31 2.500.000 3.449.387
2022-10-17 2022-10-13 4 AXLA Axcella Health Inc.
Common Stock
P - Purchase 3.048.780 3.048.780 1,64 4.999.999 4.999.999
2022-10-17 2022-10-13 4 AXLA Axcella Health Inc.
Common Stock
P - Purchase 919.111 6.299.611 17,08 1,64 1.507.342 10.331.362
2022-10-17 2022-10-13 4 AXLA Axcella Health Inc.
Common Stock
P - Purchase 914.634 5.380.500 20,48 1,64 1.500.000 8.824.020
2022-10-17 2022-10-13 4 AXLA Axcella Health Inc.
Common Stock
P - Purchase 2.757.333 14.101.638 24,31 1,64 4.522.026 23.126.686
2022-10-17 2022-10-13 4 AXLA Axcella Health Inc.
Common Stock
P - Purchase 2.743.902 11.344.305 31,90 1,64 4.499.999 18.604.660
2022-06-01 2022-05-27 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 13.698.630 13.698.630 1,46 20.000.000 20.000.000
2022-06-01 2022-05-27 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 6.849.315 8.219.791 499,78 1,46 10.000.000 12.000.895
2022-06-01 2022-05-27 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 1.369.863 5.495.324 33,21 1,46 2.000.000 8.023.173
2022-06-01 2022-05-27 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 1.095.890 1.887.419 138,45 1,46 1.599.999 2.755.632
2022-06-01 2022-05-27 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 4.383.561 7.590.873 136,67 1,46 6.399.999 11.082.675
2022-03-18 2022-03-16 4 AXLA Axcella Health Inc.
Common Stock
P - Purchase 1.579.843 4.465.866 54,74 1,91 3.017.500 8.529.804
2022-03-18 2022-03-16 4 AXLA Axcella Health Inc.
Common Stock
P - Purchase 947.905 2.004.657 89,70 1,91 1.810.499 3.828.895
2022-03-18 2022-03-16 4 AXLA Axcella Health Inc.
Common Stock
P - Purchase 3.791.623 8.600.403 78,85 1,91 7.242.000 16.426.770
2021-03-23 2021-03-19 4 RUBY Rubius Therapeutics, Inc.
Common Stock
P - Purchase 70.000 2.633.703 2,73 29,00 2.030.000 76.377.387
2021-03-23 2021-03-19 4 RUBY Rubius Therapeutics, Inc.
Common Stock
P - Purchase 70.000 2.633.703 2,73 29,00 2.030.000 76.377.387
2021-03-23 2021-03-19 4 RUBY Rubius Therapeutics, Inc.
Common Stock
P - Purchase 70.000 15.393.593 0,46 29,00 2.030.000 446.414.197
2021-02-10 2021-02-08 4 KLDO Kaleido Biosciences, Inc.
Common Stock
P - Purchase 71.667 738.333 10,75 11,50 824.170 8.490.830
2021-02-10 2021-02-08 4 KLDO Kaleido Biosciences, Inc.
Common Stock
P - Purchase 71.667 738.333 10,75 11,50 824.170 8.490.830
2021-02-10 2021-02-08 4 KLDO Kaleido Biosciences, Inc.
Common Stock
P - Purchase 71.666 1.685.444 4,44 11,50 824.159 19.382.606
2021-02-04 2021-02-02 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 46.429 4.125.461 1,14 15,00 696.435 61.881.915
2021-02-04 2021-02-02 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 37.143 1.370.476 2,79 15,00 557.145 20.557.140
2021-02-04 2021-02-02 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 37.143 1.370.476 2,79 15,00 557.145 20.557.140
2021-02-04 2021-02-02 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 9.285 791.529 1,19 15,00 139.275 11.872.935
2020-11-25 2020-11-23 4 MCRB Seres Therapeutics, Inc.
Common Stock
J - Other -43.154 0 -100,00
2020-11-25 2020-11-23 4 MCRB Seres Therapeutics, Inc.
Common Stock
J - Other -1.481.481 2.962.963 -33,33
2020-11-25 2020-11-23 4 MCRB Seres Therapeutics, Inc.
Common Stock
J - Other -1.186.310 3.258.134 -26,69
2020-11-25 2020-11-23 4 MCRB Seres Therapeutics, Inc.
Common Stock
J - Other -966.234 0 -100,00
2020-11-25 2020-11-23 4 MCRB Seres Therapeutics, Inc.
Common Stock
J - Other -642.180 1.283.282 -33,35
2020-11-25 2020-11-23 4 MCRB Seres Therapeutics, Inc.
Common Stock
J - Other -3.587.820 4.434.600 -44,72
2020-08-19 2020-08-17 4 MRNA Moderna, Inc.
Common Stock
J - Other -2.053.049 0 -100,00
2020-08-19 2020-08-17 4 MRNA Moderna, Inc.
Common Stock
J - Other -1.449.190 4.971.576 -22,57
2020-08-19 2020-08-17 4 MRNA Moderna, Inc.
Common Stock
J - Other -7.550.810 14.435.589 -34,34
2020-07-01 2020-06-29 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 1.666.667 4.079.032 69,09 3,75 6.250.001 15.296.370
2020-07-01 2020-06-29 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 1.333.333 1.333.333 3,75 4.999.999 4.999.999
2020-07-01 2020-06-29 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 1.333.333 1.333.333 3,75 4.999.999 4.999.999
2020-07-01 2020-06-29 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 333.333 782.244 74,25 3,75 1.249.999 2.933.415
2020-06-08 2020-06-04 4 KLDO Kaleido Biosciences, Inc.
Common Stock
P - Purchase 666.666 666.666 7,50 4.999.995 4.999.995
2020-06-08 2020-06-04 4 KLDO Kaleido Biosciences, Inc.
Common Stock
P - Purchase 666.667 2.910.972 29,70 7,50 5.000.002 21.832.290
2020-06-08 2020-06-04 4 KLDO Kaleido Biosciences, Inc.
Common Stock
P - Purchase 666.667 2.910.972 29,70 7,50 5.000.002 21.832.290
2020-05-26 2020-05-22 4 MRNA Moderna, Inc.
Common Stock
S - Sale -10.746 6.420.766 -0,17 70,18 -754.113 450.584.959
2020-05-26 2020-05-22 4 MRNA Moderna, Inc.
Common Stock
S - Sale -69.254 6.431.512 -1,07 69,45 -4.809.448 446.645.998
2020-05-26 2020-05-22 4 MRNA Moderna, Inc.
Common Stock
S - Sale -56.406 21.986.399 -0,26 70,18 -3.958.353 1.542.919.735
2020-05-26 2020-05-22 4 MRNA Moderna, Inc.
Common Stock
S - Sale -363.594 22.042.805 -1,62 69,45 -25.250.331 1.530.795.657
2020-05-26 2020-05-21 4 MRNA Moderna, Inc.
Common Stock
S - Sale -367 6.500.766 -0,01 72,44 -26.584 470.886.236
2020-05-26 2020-05-21 4 MRNA Moderna, Inc.
Common Stock
S - Sale -2.551 6.501.133 -0,04 71,51 -182.433 464.924.626
2020-05-26 2020-05-21 4 MRNA Moderna, Inc.
Common Stock
S - Sale -3.900 6.503.684 -0,06 70,46 -274.780 458.226.161
2020-05-26 2020-05-21 4 MRNA Moderna, Inc.
Common Stock
S - Sale -7.443 6.507.584 -0,11 68,81 -512.185 447.814.838
2020-05-26 2020-05-21 4 MRNA Moderna, Inc.
Common Stock
S - Sale -23.199 6.515.027 -0,35 67,15 -1.557.822 437.486.669
2020-05-26 2020-05-21 4 MRNA Moderna, Inc.
Common Stock
S - Sale -42.540 6.538.226 -0,65 65,77 -2.797.690 429.993.625
2020-05-26 2020-05-21 4 MRNA Moderna, Inc.
Common Stock
S - Sale -1.933 22.406.399 -0,01 72,44 -140.017 1.623.009.752
2020-05-26 2020-05-21 4 MRNA Moderna, Inc.
Common Stock
S - Sale -13.408 22.408.332 -0,06 71,51 -958.861 1.602.511.695
2020-05-26 2020-05-21 4 MRNA Moderna, Inc.
Common Stock
S - Sale -20.492 22.421.740 -0,09 70,46 -1.443.793 1.579.755.082
2020-05-26 2020-05-21 4 MRNA Moderna, Inc.
Common Stock
S - Sale -39.082 22.442.232 -0,17 68,81 -2.689.404 1.544.348.730
2020-05-26 2020-05-21 4 MRNA Moderna, Inc.
Common Stock
S - Sale -121.771 22.481.314 -0,54 67,15 -8.176.971 1.509.629.228
2020-05-26 2020-05-21 4 MRNA Moderna, Inc.
Common Stock
S - Sale -223.314 22.603.085 -0,98 65,77 -14.686.491 1.486.516.748
2020-05-20 2020-05-18 4 AXLA Axcella Health Inc.
Common Stock
P - Purchase 1.900.000 2.886.023 192,69 4,75 9.025.000 13.708.609
2020-05-20 2020-05-18 4 AXLA Axcella Health Inc.
Common Stock
P - Purchase 380.000 1.056.752 56,15 4,75 1.805.000 5.019.572
2020-05-20 2020-05-18 4 AXLA Axcella Health Inc.
Common Stock
P - Purchase 1.520.000 4.808.780 46,22 4,75 7.220.000 22.841.705
2020-05-13 2020-05-11 4 MRNA Moderna, Inc.
Common Stock
J - Other -2.281.179 0 -100,00
2020-05-13 2020-05-11 4 MRNA Moderna, Inc.
Common Stock
J - Other -1.610.000 6.580.766 -19,66
2020-05-13 2020-05-11 4 MRNA Moderna, Inc.
Common Stock
J - Other -8.390.000 22.826.399 -26,88
2019-12-11 2019-12-11 4 MRNA Moderna, Inc.
Common Stock
S - Sale -38.366 8.190.766 -0,47 18,65 -715.710 152.797.102
2019-12-11 2019-12-11 4 MRNA Moderna, Inc.
Common Stock
S - Sale -199.935 31.216.399 -0,64 18,65 -3.729.747 582.335.680
2019-12-11 2019-12-10 4 MRNA Moderna, Inc.
Common Stock
S - Sale -4.092 8.229.132 -0,05 18,96 -77.579 156.012.822
2019-12-11 2019-12-10 4 MRNA Moderna, Inc.
Common Stock
S - Sale -21.325 31.416.334 -0,07 18,96 -404.292 595.609.710
2019-12-11 2019-12-09 4 MRNA Moderna, Inc.
Common Stock
S - Sale -27.714 8.233.224 -0,34 18,99 -526.408 156.384.327
2019-12-11 2019-12-09 4 MRNA Moderna, Inc.
Common Stock
S - Sale -144.423 31.437.659 -0,46 18,99 -2.743.199 597.133.183
2019-12-11 2019-12-09 4 MRNA Moderna, Inc.
Common Stock
J - Other -1.735.720 0 -100,00
2019-12-11 2019-12-09 4 MRNA Moderna, Inc.
Common Stock
J - Other -1.207.658 8.260.938 -12,75
2019-12-11 2019-12-09 4 MRNA Moderna, Inc.
Common Stock
J - Other -6.292.342 31.582.082 -16,61
2019-10-31 2019-10-29 4 TMDX TransMedics Group, Inc.
Common Stock
J - Other -248.379 0 -100,00
2019-10-31 2019-10-29 4 TMDX TransMedics Group, Inc.
Common Stock
J - Other -61.537 0 -100,00
2019-10-31 2019-10-29 4 TMDX TransMedics Group, Inc.
Common Stock
J - Other -1.061.102 0 -100,00
2019-10-31 2019-10-29 4 TMDX TransMedics Group, Inc.
Common Stock
J - Other -1.469.173 0 -100,00
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Series E Preferred Stock
C - Conversion -895.255 0 -100,00
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Series E Preferred Stock
C - Conversion -89.525 0 -100,00
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Series E Preferred Stock
C - Conversion -358.102 0 -100,00
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Series C Preferred Stock
C - Conversion -151.643 0 -100,00
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Series C Preferred Stock
C - Conversion -617.914 0 -100,00
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Series C Preferred Stock
C - Conversion -222.506 0 -100,00
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Series B Preferred Stock
C - Conversion -1.005.413 0 -100,00
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Series B Preferred Stock
C - Conversion -928.074 0 -100,00
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Series B Preferred Stock
C - Conversion -386.697 0 -100,00
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Series A Preferred Stock
C - Conversion -4.153.847 0 -100,00
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Series A Preferred Stock
C - Conversion -1.384.615 0 -100,00
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Common Stock
P - Purchase 500.000 986.023 102,88 20,00 10.000.000 19.720.460
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Common Stock
C - Conversion 486.023 486.023
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Common Stock
C - Conversion 48.602 676.752 7,74
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Common Stock
C - Conversion 194.409 3.288.780 6,28
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Common Stock
C - Conversion 82.324 628.150 15,08
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Common Stock
C - Conversion 335.457 3.094.371 12,16
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Common Stock
C - Conversion 120.795 1.761.029 7,36
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Common Stock
C - Conversion 545.826 545.826
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Common Stock
C - Conversion 503.840 2.758.914 22,34
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Common Stock
C - Conversion 209.933 1.640.234 14,68
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Common Stock
C - Conversion 2.255.074 2.255.074
2019-05-15 2019-05-13 4 AXLA Axcella Health Inc.
Common Stock
C - Conversion 751.691 1.430.301 110,77
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
3.393.050
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
4.750.270
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
3.393.050
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
4.750.270
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
3.393.050
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
4.750.270
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
3.393.050
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
4.750.270
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
3.393.050
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
4.750.270
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
3.393.050
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
4.750.270
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
3.393.050
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
4.750.270
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
3.393.050
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
4.750.270
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
3.393.050
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
4.750.270
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
3.393.050
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
4.750.270
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
3.393.050
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
4.750.270
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
3.393.050
2019-05-08 3 AXLA Axcella Health Inc.
Common Stock
4.750.270
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Series B-1 Convertible Preferred Stock
C - Conversion -1.682.665 0 -100,00
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Series F Convertible Preferred Stock
C - Conversion -450.958 0 -100,00
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Series D Convertible Preferred Stock
C - Conversion -600.000 0 -100,00
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Series C Convertible Preferred Stock
C - Conversion -1.257.465 0 -100,00
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Series F Convertible Preferred Stock
C - Conversion -992.110 0 -100,00
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Series D Convertible Preferred Stock
C - Conversion -1.400.000 0 -100,00
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Series C Convertible Preferred Stock
C - Conversion -2.000.000 0 -100,00
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Common Stock
C - Conversion 792.366 1.061.102 294,85
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Common Stock
C - Conversion 1.254.888 1.469.173 585,62
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Common Stock
J - Other 268.736 268.736
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Common Stock
J - Other -940.579 0 -100,00
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Common Stock
J - Other 214.285 214.285
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Common Stock
J - Other -750.000 0 -100,00
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
697.306
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
751.757
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
697.306
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
751.757
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
697.306
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
751.757
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
697.306
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
751.757
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
697.306
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
751.757
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
697.306
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
751.757
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
697.306
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
751.757
2019-03-06 2019-03-04 4 KLDO Kaleido Biosciences, Inc.
Series A-1 Preferred Stock
C - Conversion -562.407 0 -100,00
2019-03-06 2019-03-04 4 KLDO Kaleido Biosciences, Inc.
Series A-1 Preferred Stock
C - Conversion -347.173 0 -100,00
2019-03-06 2019-03-04 4 KLDO Kaleido Biosciences, Inc.
Series A Preferred Stock
C - Conversion -1.331.816 0 -100,00
2019-03-06 2019-03-04 4 KLDO Kaleido Biosciences, Inc.
Common Stock
C - Conversion 281.203 947.111 42,23
2019-03-06 2019-03-04 4 KLDO Kaleido Biosciences, Inc.
Common Stock
C - Conversion 173.586 216.451 404,96
2019-03-06 2019-03-04 4 KLDO Kaleido Biosciences, Inc.
Common Stock
C - Conversion 665.908 665.908
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
3.385.728
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
3.385.728
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
3.385.728
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
3.385.728
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
3.385.728
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
3.385.728
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
3.385.728
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
3.385.728
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
3.385.728
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
1.778.594
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
3.385.728
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Series D Preferred Stock
C - Conversion -21.496 0 -100,00
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Series D Preferred Stock
C - Conversion -85.989 0 -100,00
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Series C Preferred Stock
C - Conversion -1.428.432 0 -100,00
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Series C Preferred Stock
C - Conversion -5.713.739 0 -100,00
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Series B Preferred Stock
C - Conversion -6.195.632 0 -100,00
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Series B Preferred Stock
C - Conversion -24.782.551 0 -100,00
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Series A Preferred Stock
C - Conversion -1.823.036 0 -100,00
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Series A Preferred Stock
C - Conversion -7.292.145 0 -100,00
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Common Stock
C - Conversion 21.496 9.468.596 0,23
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Common Stock
C - Conversion 85.989 37.874.424 0,23
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Common Stock
C - Conversion 1.428.432 9.447.100 17,81
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Common Stock
C - Conversion 5.713.739 37.788.435 17,81
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Common Stock
C - Conversion 6.195.632 8.018.668 339,85
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Common Stock
C - Conversion 24.782.551 32.074.696 339,85
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Common Stock
C - Conversion 1.823.036 1.823.036
2018-12-13 2018-12-11 4 MRNA Moderna, Inc.
Common Stock
C - Conversion 7.292.145 7.292.145
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
22.924.794
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
11.468.283
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
22.924.794
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
11.468.283
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
22.924.794
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
11.468.283
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
22.924.794
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
11.468.283
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
22.924.794
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
11.468.283
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
22.924.794
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
11.468.283
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
22.924.794
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
11.468.283
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
22.924.794
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
11.468.283
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
22.924.794
2018-12-07 3 MRNA Moderna, Inc.
Common Stock
11.468.283
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -781.860 0 -100,00
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -195.466 0 -100,00
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -195.466 0 -100,00
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -1.781.843 0 -100,00
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -593.948 0 -100,00
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -593.948 0 -100,00
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -5.000.000 0 -100,00
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -5.000.000 0 -100,00
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -3.830.402 0 -100,00
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -15.323.593 0 -100,00
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Common Stock
C - Conversion 781.860 2.563.703 43,88
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Common Stock
C - Conversion 195.466 5.789.414 3,49
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Common Stock
C - Conversion 195.466 5.789.414 3,49
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Common Stock
C - Conversion 1.781.843 1.781.843
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Common Stock
C - Conversion 593.948 5.593.948 11,88
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Common Stock
C - Conversion 593.948 5.593.948 11,88
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Common Stock
C - Conversion 5.000.000 5.000.000
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Common Stock
C - Conversion 5.000.000 5.000.000
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Common Stock
C - Conversion 3.830.402 3.830.402
2018-07-23 2018-07-20 4 RUBY Rubius Therapeutics, Inc.
Common Stock
C - Conversion 15.323.593 15.323.593
2018-07-17 3 RUBY Rubius Therapeutics, Inc.
Common Stock
10.000.000
2018-07-17 3 RUBY Rubius Therapeutics, Inc.
Common Stock
10.000.000
2018-07-17 3 RUBY Rubius Therapeutics, Inc.
Common Stock
10.000.000
2018-07-17 3 RUBY Rubius Therapeutics, Inc.
Common Stock
10.000.000
2018-07-17 3 RUBY Rubius Therapeutics, Inc.
Common Stock
10.000.000
2018-07-17 3 RUBY Rubius Therapeutics, Inc.
Common Stock
10.000.000
2018-07-17 3 RUBY Rubius Therapeutics, Inc.
Common Stock
10.000.000
2018-07-17 3 RUBY Rubius Therapeutics, Inc.
Common Stock
10.000.000
2018-07-17 3 RUBY Rubius Therapeutics, Inc.
Common Stock
10.000.000
2018-07-17 3 RUBY Rubius Therapeutics, Inc.
Common Stock
10.000.000
2018-07-17 3 RUBY Rubius Therapeutics, Inc.
Common Stock
10.000.000
2018-05-15 2018-05-11 4 EVLO Evelo Biosciences, Inc.
Series C Preferred Stock
C - Conversion -4.643.963 0 -100,00
2018-05-15 2018-05-11 4 EVLO Evelo Biosciences, Inc.
Series B Preferred Stock
C - Conversion -18.611.110 0 -100,00
2018-05-15 2018-05-11 4 EVLO Evelo Biosciences, Inc.
Series A-3 Preferred Stock
C - Conversion -8.333.000 0 -100,00
2018-05-15 2018-05-11 4 EVLO Evelo Biosciences, Inc.
Series A-2 Preferred Stock
C - Conversion -5.416.667 0 -100,00
2018-05-15 2018-05-11 4 EVLO Evelo Biosciences, Inc.
Series A-1 Preferred Stock
C - Conversion -10.102.055 0 -100,00
2018-05-15 2018-05-11 4 EVLO Evelo Biosciences, Inc.
Series A Preferred Stock
C - Conversion -12.536.945 0 -100,00
2018-05-15 2018-05-11 4 EVLO Evelo Biosciences, Inc.
Common Stock
P - Purchase 281.250 18.233.403 1,57 16,00 4.500.000 291.734.448
2018-05-15 2018-05-11 4 EVLO Evelo Biosciences, Inc.
Common Stock
C - Conversion 14.622.143 17.952.153 439,10
2018-05-08 3 EVLO Evelo Biosciences, Inc.
Common Stock
6.660.018
2018-05-08 3 EVLO Evelo Biosciences, Inc.
Common Stock
6.660.018
2018-05-08 3 EVLO Evelo Biosciences, Inc.
Common Stock
6.660.018
2018-05-08 3 EVLO Evelo Biosciences, Inc.
Common Stock
6.660.018
2018-05-08 3 EVLO Evelo Biosciences, Inc.
Common Stock
6.660.018
2018-05-08 3 EVLO Evelo Biosciences, Inc.
Common Stock
6.660.018
2017-08-21 2017-08-17 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
J - Other -54.293 0 -100,00
2017-08-21 2017-08-17 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
J - Other -306.222 612.442 -33,33
2017-08-21 2017-08-17 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
J - Other -1.295.997 2.378.663 -35,27
2016-09-26 2016-09-23 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -10.293 106.787 -8,79 3,10 -31.908 331.040
2016-09-26 2016-09-23 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -41.178 426.885 -8,80 3,10 -127.652 1.323.344
2016-09-26 2016-09-23 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -3.118 117.080 -2,59 3,16 -9.853 369.973
2016-09-26 2016-09-23 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -12.482 468.063 -2,60 3,16 -39.443 1.479.079
2016-09-26 2016-09-22 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -47.090 120.198 -28,15 3,17 -149.275 381.028
2016-09-26 2016-09-22 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -188.367 480.545 -28,16 3,17 -597.123 1.523.328
2016-09-26 2016-09-22 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -28.163 167.288 -14,41 3,18 -89.558 531.976
2016-09-26 2016-09-22 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -112.731 668.912 -14,42 3,18 -358.485 2.127.140
2016-09-21 2016-09-21 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -64.509 195.451 -24,81 3,75 -241.909 732.941
2016-09-21 2016-09-21 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -258.214 781.643 -24,83 3,75 -968.302 2.931.161
2016-09-21 2016-09-20 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -10.778 259.960 -3,98 3,39 -36.537 881.264
2016-09-21 2016-09-20 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -43.139 1.039.857 -3,98 3,39 -146.241 3.525.115
2016-09-21 2016-09-19 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -1.939 270.738 -0,71 3,31 -6.418 896.143
2016-09-21 2016-09-19 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -7.761 1.082.996 -0,71 3,31 -25.689 3.584.717
2016-09-16 2016-09-15 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -536 272.677 -0,20 4,16 -2.230 1.134.336
2016-09-16 2016-09-15 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -2.145 1.090.757 -0,20 4,16 -8.923 4.537.549
2016-09-16 2016-09-14 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -8.802 273.213 -3,12 4,18 -36.792 1.142.030
2016-09-16 2016-09-14 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -35.209 1.092.902 -3,12 4,18 -147.174 4.568.330
2016-09-08 2016-09-07 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -8.145 282.015 -2,81 4,51 -36.734 1.271.888
2016-09-08 2016-09-07 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -32.597 1.128.111 -2,81 4,51 -147.012 5.087.781
2016-09-08 2016-09-07 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -52.985 1.833.802 -2,81 4,51 -238.962 8.270.447
2016-09-08 2016-09-06 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -3.108 290.160 -1,06 4,63 -14.390 1.343.441
2016-09-08 2016-09-06 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -12.441 1.160.708 -1,06 4,63 -57.602 5.374.078
2016-09-08 2016-09-06 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
S - Sale -20.221 1.886.787 -1,06 4,63 -93.623 8.735.824
2016-08-15 2016-08-11 4 EDIT Editas Medicine, Inc.
Common Stock
J - Other -50.271 0 -100,00
2016-08-15 2016-08-11 4 EDIT Editas Medicine, Inc.
Common Stock
J - Other -300.000 691.060 -30,27
2016-08-15 2016-08-11 4 EDIT Editas Medicine, Inc.
Common Stock
J - Other -1.200.000 2.764.256 -30,27
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series B Preferred Stock
C - Conversion -444.995 0 -100,00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series B Preferred Stock
C - Conversion -1.779.981 0 -100,00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series A-3 Preferred Stock
C - Conversion -1.500.000 0 -100,00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series A-3 Preferred Stock
C - Conversion -6.000.000 0 -100,00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock
C - Conversion -1.000.000 0 -100,00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock
C - Conversion -4.000.000 0 -100,00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series A-1 Preferred Stock
C - Conversion -200.000 0 -100,00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series A-1 Preferred Stock
C - Conversion -800.000 0 -100,00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
P - Purchase 80.000 918.664 9,54 12,50 1.000.000 11.483.300
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
P - Purchase 320.000 3.674.660 9,54 12,50 4.000.000 45.933.250
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 118.665 838.664 16,48
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 474.661 3.354.660 16,48
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 400.000 719.999 125,00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 1.600.000 2.879.999 125,00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 266.666 319.999 500,00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 1.066.666 1.279.999 500,00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 53.333 53.333
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 213.333 213.333
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
426.664
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
426.664
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
426.664
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
426.664
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
426.664
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
426.664
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
426.664
2016-05-27 2016-05-25 4 MCRB Seres Therapeutics, Inc.
Common Stock, $0.001 par value
J - Other -33.514 0 -100,00
2016-05-27 2016-05-25 4 MCRB Seres Therapeutics, Inc.
Common Stock, $0.001 par value
J - Other 7 33.514 0,02
2016-05-27 2016-05-25 4 MCRB Seres Therapeutics, Inc.
Common Stock, $0.001 par value
J - Other 33.507 33.514 478.671,43
2016-05-27 2016-05-25 4 MCRB Seres Therapeutics, Inc.
Common Stock, $0.001 par value
J - Other -200.000 1.925.462 -9,41
2016-05-27 2016-05-25 4 MCRB Seres Therapeutics, Inc.
Common Stock, $0.001 par value
J - Other -800.000 8.022.420 -9,07
2016-05-27 2016-05-25 4 MCRB Seres Therapeutics, Inc.
Common Stock, $0.001 par value
S - Sale -599.297 0 -100,00 27,60 -16.540.597
2016-05-27 2016-05-25 4 MCRB Seres Therapeutics, Inc.
Common Stock, $0.001 par value
S - Sale -80.141 1.925.462 -4,00 27,60 -2.211.892 53.142.751
2016-05-27 2016-05-25 4 MCRB Seres Therapeutics, Inc.
Common Stock, $0.001 par value
S - Sale -320.562 2.734.994 -10,49 27,60 -8.847.511 75.485.834
2016-02-09 2016-02-08 4 EDIT Editas Medicine, Inc.
Series B Preferred Stock
C - Conversion -199.999 0 -100,00
2016-02-09 2016-02-08 4 EDIT Editas Medicine, Inc.
Series A-2 Preferred Stock
C - Conversion -1.051.060 0 -100,00
2016-02-09 2016-02-08 4 EDIT Editas Medicine, Inc.
Series A-1 Preferred Stock
C - Conversion -1.325.708 0 -100,00
2016-02-09 2016-02-08 4 EDIT Editas Medicine, Inc.
Series B Preferred Stock
C - Conversion -800.001 0 -100,00
2016-02-09 2016-02-08 4 EDIT Editas Medicine, Inc.
Series A-2 Preferred Stock
C - Conversion -4.204.240 0 -100,00
2016-02-09 2016-02-08 4 EDIT Editas Medicine, Inc.
Series A-1 Preferred Stock
C - Conversion -5.302.834 0 -100,00
2016-02-09 2016-02-08 4 EDIT Editas Medicine, Inc.
Common Stock
C - Conversion 76.922 991.060 8,41
2016-02-09 2016-02-08 4 EDIT Editas Medicine, Inc.
Common Stock
C - Conversion 404.253 914.138 79,28
2016-02-09 2016-02-08 4 EDIT Editas Medicine, Inc.
Common Stock
C - Conversion 509.885 509.885
2016-02-09 2016-02-08 4 EDIT Editas Medicine, Inc.
Common Stock
C - Conversion 307.692 3.964.256 8,41
2016-02-09 2016-02-08 4 EDIT Editas Medicine, Inc.
Common Stock
C - Conversion 1.617.015 3.656.564 79,28
2016-02-09 2016-02-08 4 EDIT Editas Medicine, Inc.
Common Stock
C - Conversion 2.039.549 2.039.549
2015-06-29 2015-06-26 4 MCRB Seres Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -454.546 0 -100,00
2015-06-29 2015-06-26 4 MCRB Seres Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -1.818.181 0 -100,00
2015-06-29 2015-06-26 4 MCRB Seres Therapeutics, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -224.719 0 -100,00
2015-06-29 2015-06-26 4 MCRB Seres Therapeutics, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -898.877 0 -100,00
2015-06-29 2015-06-26 4 MCRB Seres Therapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -599.297 0 -100,00
2015-06-29 2015-06-26 4 MCRB Seres Therapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -1.526.338 0 -100,00
2015-06-29 2015-06-26 4 MCRB Seres Therapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -6.105.362 0 -100,00
2015-06-29 2015-06-26 4 MCRB Seres Therapeutics, Inc.
Common Stock, $0.001 par value
C - Conversion 599.297 599.297
2015-06-29 2015-06-26 4 MCRB Seres Therapeutics, Inc.
Common Stock, $0.001 par value
C - Conversion 2.205.603 2.205.603
2015-06-29 2015-06-26 4 MCRB Seres Therapeutics, Inc.
Common Stock, $0.001 par value
C - Conversion 8.822.420 8.822.420
2015-06-29 2015-06-25 4 MCRB Seres Therapeutics, Inc.
Stock Option (right to buy)
A - Award 15.000 15.000
2015-06-25 3 MCRB Seres Therapeutics, Inc.
Common Stock
6.111.112
2015-06-25 3 MCRB Seres Therapeutics, Inc.
Common Stock
6.111.112
2015-06-25 3 MCRB Seres Therapeutics, Inc.
Common Stock
6.111.112
2015-06-25 3 MCRB Seres Therapeutics, Inc.
Common Stock
6.111.112
2015-06-25 3 MCRB Seres Therapeutics, Inc.
Common Stock
6.111.112
2015-06-25 3 MCRB Seres Therapeutics, Inc.
Common Stock
6.111.112
2015-06-25 3 MCRB Seres Therapeutics, Inc.
Common Stock
6.111.112
2015-06-25 3 MCRB Seres Therapeutics, Inc.
Common Stock
6.111.112
2015-06-25 3 MCRB Seres Therapeutics, Inc.
Common Stock
6.111.112
2014-08-14 2014-08-12 4 TTOO T2 Biosystems, Inc.
Series E Convertible Preferred Stock
C - Conversion -631.133 0 -100,00
2014-08-14 2014-08-12 4 TTOO T2 Biosystems, Inc.
Series D Convertible Preferred Stock
C - Conversion -629.851 0 -100,00
2014-08-14 2014-08-12 4 TTOO T2 Biosystems, Inc.
Series C Convertible Preferred Stock
C - Conversion -819.493 0 -100,00
2014-08-14 2014-08-12 4 TTOO T2 Biosystems, Inc.
Series B Convertible Preferred Stock
C - Conversion -1.053.201 0 -100,00
2014-08-14 2014-08-12 4 TTOO T2 Biosystems, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -774.527 0 -100,00
2014-08-14 2014-08-12 4 TTOO T2 Biosystems, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -128.567 0 -100,00
2014-08-14 2014-08-12 4 TTOO T2 Biosystems, Inc.
Common Stock
C - Conversion 741.755 2.374.571 45,43
2014-08-14 2014-08-12 4 TTOO T2 Biosystems, Inc.
Common Stock
C - Conversion 1.632.816 1.632.816
2014-02-13 2014-02-11 4 EBIO Eleven Biotherapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -420.053 0 -100,00
2014-02-13 2014-02-11 4 EBIO Eleven Biotherapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -1.680.213 0 -100,00
2014-02-13 2014-02-11 4 EBIO Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -1.050.000 0 -100,00
2014-02-13 2014-02-11 4 EBIO Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -4.200.000 0 -100,00
2014-02-13 2014-02-11 4 EBIO Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -9.000.000 0 -100,00
2014-02-13 2014-02-11 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
P - Purchase 32.912 293.268 12,64 10,00 329.120 2.932.680
2014-02-13 2014-02-11 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
P - Purchase 131.722 1.173.149 12,65 10,00 1.317.220 11.731.490
2014-02-13 2014-02-11 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
P - Purchase 214.095 1.907.008 12,65 10,00 2.140.950 19.070.080
2014-02-13 2014-02-11 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
C - Conversion 231.504 260.356 802,38
2014-02-13 2014-02-11 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
C - Conversion 926.017 1.041.427 802,37
2014-02-13 2014-02-11 4 EBIO Eleven Biotherapeutics, Inc.
Common Stock
C - Conversion 1.417.323 1.692.913 514,29
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
695.442
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
535.262
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
448.704
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
695.442
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
535.262
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
448.704
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
695.442
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
535.262
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
448.704
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
695.442
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
535.262
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
448.704
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
695.442
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
535.262
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
448.704
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
695.442
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
535.262
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
448.704
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
695.442
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
535.262
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
448.704
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
275.590
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
115.410
2014-02-05 3 EBIO Eleven Biotherapeutics, Inc.
Common Stock
28.852
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)